Xenetic Biosciences is trading 5.66% lower at $2.33, with no company-specific announcement or confirmed catalyst identified for September 25, 2026. - The stock closed at $2.47 on September 24, 2026, and is extending its weakness. - The previously announced Santersus all-stock acquisition remains the latest major disclosure; available coverage does not directly link it to the session’s decline.